MedDataX Logo

Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®

NCT ID: NCT01608672

Last Updated: 2019-04-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

207 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-01

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study assessing patient satisfaction following at least 5 years of BOTOX® treatment for glabellar lines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines

NCT00856414

Skin Aging
COMPLETED PHASE4

A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

NCT06218251

Upper Facial Lines
COMPLETED PHASE4

Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

NCT02303002

Glabellar Frown Lines
COMPLETED PHASE2

An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A

NCT01608659

Facial Rhytides
COMPLETED

Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines

NCT01271452

Glabellar Lines
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glabellar Lines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All participants

Botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.

botulinum toxin Type A

Intervention Type BIOLOGICAL

botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

botulinum toxin Type A

botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BOTOX® OnabotulinumtoxinA BOTOX® Cosmetic Vistabel®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least one BOTOX® treatment for facial wrinkles (glabellar lines) per calendar year for ≥5 years

Exclusion Criteria

* Received botulinum toxin formulations other than BOTOX®
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allergan

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Allergan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Coral Gables, Florida, United States

Site Status

South Yarra, , Australia

Site Status

São Paulo, , Brazil

Site Status

Niagara Falls, Ontario, Canada

Site Status

Cannes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Brazil Canada France

References

Explore related publications, articles, or registry entries linked to this study.

Trindade de Almeida A, Carruthers J, Cox SE, Goldman MP, Wheeler S, Gallagher CJ. Patient satisfaction and safety with aesthetic onabotulinumtoxinA after at least 5 years: a retrospective cross-sectional analysis of 4,402 glabellar treatments. Dermatol Surg. 2015 Jan;41 Suppl 1:S19-28. doi: 10.1097/DSS.0000000000000275.

Reference Type BACKGROUND
PMID: 25548841 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GMA-BTXC-11-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants
NCT06174688 COMPLETED PHASE3
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
NCT05496335 COMPLETED PHASE1
Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
NCT01814670 COMPLETED PHASE4
A Study Of BOTOX For The Treatment Of Glabellar Lines
NCT00408785 COMPLETED PHASE3
A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides
NCT01777620 COMPLETED PHASE4
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
NCT05013424 COMPLETED PHASE2
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
NCT05248867 COMPLETED PHASE3
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
NCT01485601 COMPLETED PHASE2
A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides
NCT02261467 COMPLETED PHASE3
Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line
NCT03908008 COMPLETED PHASE3
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
NCT02043145 COMPLETED
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
NCT05248880 COMPLETED PHASE3
Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.
NCT05380154 COMPLETED PHASE3
Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients
NCT01004042 COMPLETED PHASE4
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
NCT03861936 COMPLETED PHASE2
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
NCT06583486 ACTIVE_NOT_RECRUITING PHASE3
A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
NCT06161246 COMPLETED PHASE4
Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines
NCT04631588 COMPLETED PHASE1
Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines
NCT05801146 RECRUITING PHASE3
Study Comparing Treatment With Alluzience vs Reconstituted Toxin
NCT05277337 COMPLETED PHASE4
Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines
NCT05766683 ACTIVE_NOT_RECRUITING PHASE1
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
NCT02677805 COMPLETED PHASE3
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
NCT05743634 COMPLETED PHASE1/PHASE2
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
NCT04830345 COMPLETED PHASE3
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
NCT01391299 COMPLETED NA